Highlights of June 2020
India – Most active in June 2020
- Carlyle, Piramal Pharma ink 20% strategic growth investment worth $490 Million.
- CEPI grants US$14.1 Million to Bharat Biotech, IVI for advancing Chikungunya vaccine.
- Cipla buys 21.85% stake in health-tech startup GoApptiv for US$1.19 Million.
- Lupin inks distribution pact in Europe with 3 firms to commercialize NaMuscla.
- SMT (Sahajanand Medical Technologies Pvt Ltd) announces its entry into the structural heart segment with an acquisition of medical device firm Vascular Concepts.
- Oxford COVID vaccine: AstraZeneca inks pact with India's Serum Institute of India, others to supply 2 billion doses.
- Panacea Biotec, Refana announce landmark collaboration for COVID-19 vaccine.
- Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region.
- Piramal Pharma acquires SODD facility from G&W Labs.
- Naari Pharma Pvt. Ltd. has entered into a definitive asset purchase agreement to acquire 10 Abbreviated New Drug Applications (ANDAs) for the U.S. market from Intas Pharmaceuticals Ltd.
- Roche Products (India) Pvt. Ltd. (Roche Pharma) and Cipla Limited have announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India.
- Cipla, Boehringer Ingelheim To Co-Market Oral Anti-Diabetic Drugs Oboravo, Oboravo Met, Tiptengio.
Other International Deals
- Emergent BioSolutions, BARDA reach US$628 Million deal to manufacture COVID-19 vaccine hopefuls.
- Merck pens US$500 Million Yumanity pact, nabbing 2 neuro hopefuls in the process.
- CSL to pay US$450 Million to buy uniQure's hemophilia B gene therapy.
- PharmaMar out-licenses Yondelis to Taiwanese company.
- CSL Behring to acquire Canadian biotech company Vitaeris.
- Bayer-backed Century buys Empirica to create brain cancer CAR-Ts.
- Agenus pens licensing deal for balstilimab and zalifrelimab in Greater China.
- University of Copenhagen spinout enters license agreement with Bavarian Nordic.
- Novo Nordisk to acquire Corvidia Therapeutics.
Highlights at Aagami
- New Client Win: US Innovator bringing Confluence of Portable MRI, Robotics & AI in a Physician's Office
- BIO Digital 2020: Aagami has successfully completed BIO Digital 2020 with 50+ Executive level meetings along with representing multiple clients
Some of the partnering opportunities available at Aagami are:
Available for Acquisition:
- PharmaPEG® technology - IP Portfolio & all associated data package to make Next-Generation Bio-Therapeutics.
- The related company is also open for acquisition.
For Investors:
- Seeking US$10M in Current Tranche of Series B for US Innovator bringing Confluence of Portable MRI, Robotics & AI in a Physician's Office. The company has already raised first tranche of Series B-1 ($15M+)
- Seeking US$1.5M for Drug-device to delay the progression of Parkinson’s disease (PD), prevent Asian Flush and Hangover.
- Seeking US$1M for expansion of an Oncology focused healthcare and data science company.
For Licensing/Partnering/Co-development:
- Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
- On the Market Pro-immunity anti-cancer capsules of Rapid and synchronized dormancy-broken Kyoho grape seed endosperm from our Japanese client.